 Milene Saavedra
Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 29 | 2025 | 1161 | 2.900 |
Why?
| | Rhinitis | 9 | 2025 | 169 | 1.570 |
Why?
| | Sinusitis | 9 | 2025 | 227 | 1.490 |
Why?
| | Pseudomonas Infections | 10 | 2022 | 230 | 1.370 |
Why?
| | Pseudomonas aeruginosa | 12 | 2023 | 395 | 0.840 |
Why?
| | Azithromycin | 6 | 2020 | 101 | 0.620 |
Why?
| | Anti-Bacterial Agents | 10 | 2022 | 1923 | 0.540 |
Why?
| | C-Reactive Protein | 2 | 2018 | 422 | 0.480 |
Why?
| | Neutrophils | 6 | 2020 | 1124 | 0.470 |
Why?
| | Olfaction Disorders | 3 | 2025 | 70 | 0.450 |
Why?
| | Tobramycin | 5 | 2019 | 63 | 0.420 |
Why?
| | Aminophenols | 4 | 2024 | 202 | 0.410 |
Why?
| | Gene Expression Profiling | 4 | 2018 | 1767 | 0.410 |
Why?
| | Mycobacterium Infections, Nontuberculous | 3 | 2022 | 339 | 0.380 |
Why?
| | Respiratory Mucosa | 2 | 2008 | 322 | 0.370 |
Why?
| | Chronic Disease | 9 | 2025 | 1808 | 0.340 |
Why?
| | Mycobacterium abscessus | 2 | 2022 | 110 | 0.300 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 7 | 2024 | 371 | 0.300 |
Why?
| | Radiographic Image Enhancement | 1 | 2009 | 57 | 0.290 |
Why?
| | Prospective Studies | 9 | 2025 | 8057 | 0.290 |
Why?
| | Kruppel-Like Transcription Factors | 2 | 2008 | 82 | 0.270 |
Why?
| | RNA Precursors | 1 | 2008 | 154 | 0.250 |
Why?
| | Minimal Clinically Important Difference | 2 | 2024 | 31 | 0.250 |
Why?
| | Smell | 2 | 2025 | 126 | 0.250 |
Why?
| | Benzodioxoles | 3 | 2024 | 161 | 0.250 |
Why?
| | Radiology | 1 | 2009 | 174 | 0.250 |
Why?
| | Sputum | 4 | 2022 | 302 | 0.230 |
Why?
| | Administration, Inhalation | 3 | 2022 | 571 | 0.220 |
Why?
| | Quality of Life | 4 | 2025 | 3204 | 0.210 |
Why?
| | Biomarkers | 5 | 2022 | 4295 | 0.200 |
Why?
| | Forced Expiratory Volume | 6 | 2019 | 450 | 0.200 |
Why?
| | Food Preferences | 1 | 2025 | 126 | 0.200 |
Why?
| | Indoles | 2 | 2024 | 507 | 0.190 |
Why?
| | Leukocytes | 2 | 2018 | 296 | 0.190 |
Why?
| | Medication Adherence | 2 | 2025 | 540 | 0.190 |
Why?
| | Lipopolysaccharides | 2 | 2020 | 858 | 0.170 |
Why?
| | Humans | 36 | 2025 | 145474 | 0.170 |
Why?
| | Self Efficacy | 1 | 2025 | 410 | 0.170 |
Why?
| | Adult | 17 | 2025 | 40777 | 0.160 |
Why?
| | Quinolones | 4 | 2024 | 203 | 0.160 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2769 | 0.150 |
Why?
| | Aztreonam | 2 | 2016 | 11 | 0.150 |
Why?
| | Feedback | 1 | 2020 | 180 | 0.150 |
Why?
| | Inflammation | 3 | 2022 | 2878 | 0.150 |
Why?
| | Colistin | 1 | 2019 | 10 | 0.150 |
Why?
| | Iron | 1 | 2002 | 357 | 0.150 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 318 | 0.150 |
Why?
| | Receptors, Interleukin-8B | 1 | 2018 | 29 | 0.140 |
Why?
| | British Columbia | 1 | 2018 | 24 | 0.140 |
Why?
| | Mental Health | 1 | 2025 | 793 | 0.140 |
Why?
| | Severity of Illness Index | 4 | 2024 | 2930 | 0.130 |
Why?
| | Anxiety | 1 | 2025 | 1118 | 0.130 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 361 | 0.130 |
Why?
| | Disease Progression | 4 | 2019 | 2864 | 0.130 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.130 |
Why?
| | Male | 20 | 2025 | 72842 | 0.120 |
Why?
| | Drug Combinations | 3 | 2024 | 396 | 0.120 |
Why?
| | Female | 20 | 2025 | 78844 | 0.120 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 484 | 0.110 |
Why?
| | Interferons | 1 | 2016 | 186 | 0.110 |
Why?
| | Depression | 1 | 2025 | 1546 | 0.110 |
Why?
| | Young Adult | 8 | 2024 | 14218 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 42 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2022 | 2803 | 0.100 |
Why?
| | Quorum Sensing | 1 | 2014 | 80 | 0.100 |
Why?
| | Interleukin-8 | 2 | 2020 | 269 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 977 | 0.100 |
Why?
| | Apoptosis | 1 | 2002 | 2440 | 0.100 |
Why?
| | Survival Rate | 1 | 2018 | 2090 | 0.100 |
Why?
| | Lung | 5 | 2023 | 4106 | 0.100 |
Why?
| | Cytokines | 3 | 2015 | 2067 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 174 | 0.090 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 55 | 0.090 |
Why?
| | Neutrophil Activation | 1 | 2013 | 84 | 0.090 |
Why?
| | Wound Infection | 1 | 2013 | 60 | 0.090 |
Why?
| | Prognosis | 2 | 2018 | 4316 | 0.090 |
Why?
| | Mycobacterium | 1 | 2013 | 101 | 0.090 |
Why?
| | Promoter Regions, Genetic | 2 | 2008 | 1246 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 6 | 0.090 |
Why?
| | Biofilms | 3 | 2014 | 292 | 0.090 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 6066 | 0.090 |
Why?
| | Endoscopy | 2 | 2024 | 317 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2020 | 2597 | 0.080 |
Why?
| | Microbial Viability | 1 | 2011 | 83 | 0.080 |
Why?
| | Extracellular Space | 1 | 2011 | 117 | 0.080 |
Why?
| | Treatment Outcome | 6 | 2024 | 11772 | 0.080 |
Why?
| | Enzyme Induction | 2 | 2008 | 88 | 0.080 |
Why?
| | Nontuberculous Mycobacteria | 2 | 2022 | 189 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2008 | 1217 | 0.080 |
Why?
| | Colorado | 2 | 2018 | 4553 | 0.080 |
Why?
| | Paranasal Sinuses | 2 | 2024 | 81 | 0.080 |
Why?
| | Middle Aged | 10 | 2025 | 36215 | 0.070 |
Why?
| | Pyridines | 2 | 2024 | 609 | 0.070 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2121 | 0.070 |
Why?
| | Protein Array Analysis | 1 | 2009 | 56 | 0.070 |
Why?
| | Transcription, Genetic | 2 | 2008 | 1454 | 0.070 |
Why?
| | Nasal Polyps | 1 | 2009 | 59 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2023 | 892 | 0.070 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5423 | 0.070 |
Why?
| | Time Factors | 2 | 2018 | 7123 | 0.070 |
Why?
| | Mutation | 2 | 2021 | 4075 | 0.070 |
Why?
| | Burns | 1 | 2013 | 374 | 0.070 |
Why?
| | Spirometry | 1 | 2008 | 233 | 0.070 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 162 | 0.070 |
Why?
| | NF-kappa B | 2 | 2008 | 666 | 0.060 |
Why?
| | Case-Control Studies | 4 | 2020 | 3623 | 0.060 |
Why?
| | Interleukins | 1 | 2008 | 248 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 749 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 617 | 0.060 |
Why?
| | Survivors | 1 | 2010 | 523 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2008 | 762 | 0.060 |
Why?
| | Aspirin | 1 | 2009 | 406 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1036 | 0.060 |
Why?
| | Cell Line | 2 | 2008 | 2823 | 0.050 |
Why?
| | Phospholipases A | 1 | 2005 | 97 | 0.050 |
Why?
| | Cytosol | 1 | 2005 | 213 | 0.050 |
Why?
| | Cohort Studies | 2 | 2020 | 6013 | 0.050 |
Why?
| | Epithelial Cells | 2 | 2008 | 1131 | 0.050 |
Why?
| | Drug Interactions | 2 | 2016 | 405 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 133 | 0.050 |
Why?
| | Pseudomonas | 1 | 2023 | 30 | 0.050 |
Why?
| | Logistic Models | 2 | 2019 | 2134 | 0.050 |
Why?
| | Cell Separation | 2 | 2016 | 305 | 0.050 |
Why?
| | Pyrrolidines | 1 | 2023 | 125 | 0.050 |
Why?
| | Trans-Activators | 1 | 2005 | 396 | 0.050 |
Why?
| | Social Class | 1 | 2024 | 264 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 119 | 0.040 |
Why?
| | HIV-1 | 1 | 2008 | 908 | 0.040 |
Why?
| | Self-Management | 1 | 2025 | 202 | 0.040 |
Why?
| | Chemokine CCL2 | 1 | 2002 | 112 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2014 | 364 | 0.040 |
Why?
| | Protease Inhibitors | 1 | 2002 | 102 | 0.040 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 31 | 0.040 |
Why?
| | Anti-HIV Agents | 1 | 2008 | 912 | 0.040 |
Why?
| | Chloroquine | 1 | 2020 | 54 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2008 | 3413 | 0.040 |
Why?
| | Bronchi | 1 | 2002 | 263 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2020 | 172 | 0.040 |
Why?
| | Pyrazoles | 1 | 2023 | 517 | 0.040 |
Why?
| | Tetraspanin 30 | 1 | 2018 | 10 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2008 | 4148 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2002 | 452 | 0.040 |
Why?
| | Sirolimus | 1 | 2020 | 280 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 172 | 0.040 |
Why?
| | Phagocytosis | 1 | 2020 | 296 | 0.030 |
Why?
| | Survival Analysis | 2 | 2016 | 1374 | 0.030 |
Why?
| | Homozygote | 1 | 2018 | 199 | 0.030 |
Why?
| | Sex Factors | 1 | 2024 | 2105 | 0.030 |
Why?
| | Aminopyridines | 1 | 2018 | 129 | 0.030 |
Why?
| | Autophagy | 1 | 2020 | 291 | 0.030 |
Why?
| | Child | 3 | 2020 | 22707 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 2020 | 611 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 425 | 0.030 |
Why?
| | Gene Deletion | 1 | 2018 | 391 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 42 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 838 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 193 | 0.030 |
Why?
| | Genotype | 2 | 2014 | 1852 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 544 | 0.030 |
Why?
| | Retrospective Studies | 4 | 2019 | 17291 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1891 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 51 | 0.030 |
Why?
| | RNA, Small Interfering | 2 | 2008 | 637 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 77 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 969 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1082 | 0.020 |
Why?
| | Chlorides | 1 | 2014 | 138 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2025 | 5904 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2016 | 401 | 0.020 |
Why?
| | Ciprofloxacin | 1 | 2013 | 31 | 0.020 |
Why?
| | Adolescent | 3 | 2020 | 22529 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1547 | 0.020 |
Why?
| | Superoxides | 1 | 2013 | 198 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 354 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 28 | 0.020 |
Why?
| | Mice | 2 | 2023 | 18329 | 0.020 |
Why?
| | Risk Factors | 2 | 2016 | 10885 | 0.020 |
Why?
| | DNA | 2 | 2008 | 1435 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2013 | 1044 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 451 | 0.020 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 2 | 0.020 |
Why?
| | Caspase 8 | 1 | 2009 | 47 | 0.020 |
Why?
| | Caspase 9 | 1 | 2009 | 55 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 403 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 387 | 0.020 |
Why?
| | Animals | 3 | 2023 | 38030 | 0.020 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 75 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2009 | 99 | 0.020 |
Why?
| | HIV Core Protein p24 | 1 | 2008 | 32 | 0.020 |
Why?
| | Age of Onset | 1 | 2010 | 555 | 0.020 |
Why?
| | Transcription Factor AP-1 | 1 | 2008 | 79 | 0.020 |
Why?
| | Signal Transduction | 1 | 2020 | 5216 | 0.020 |
Why?
| | Phospholipases A2 | 1 | 2005 | 79 | 0.010 |
Why?
| | Up-Regulation | 1 | 2008 | 847 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2005 | 59 | 0.010 |
Why?
| | Group IV Phospholipases A2 | 1 | 2005 | 46 | 0.010 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2004 | 24 | 0.010 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2005 | 88 | 0.010 |
Why?
| | Drosophila | 1 | 2005 | 164 | 0.010 |
Why?
| | Early Diagnosis | 1 | 2004 | 251 | 0.010 |
Why?
| | Patient Acceptance of Health Care | 1 | 2010 | 881 | 0.010 |
Why?
| | Actins | 1 | 2005 | 425 | 0.010 |
Why?
| | Transfection | 1 | 2005 | 926 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2013 | 4560 | 0.010 |
Why?
| | Protein Binding | 1 | 2008 | 2238 | 0.010 |
Why?
| | Registries | 1 | 2010 | 2406 | 0.010 |
Why?
| | Phosphorylation | 1 | 2005 | 1707 | 0.010 |
Why?
| | Aged | 2 | 2010 | 26153 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2005 | 3542 | 0.010 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2005 | 1189 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2005 | 2664 | 0.010 |
Why?
| | Child, Preschool | 1 | 2004 | 11853 | 0.000 |
Why?
|
|
Saavedra's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|